Clinical Trial Update: Efficacy and Tolerability of ABT-869 Versus Sorafenib in Advanced Hepatocellular Carcinoma (HCC) [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing ABT-869 (linifanib) to sorafenib in advanced hepatocellular carcinoma was terminated; the update reports on efficacy and tolerability …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• ABT-869 (linifanib)
• Nexavar (Sorafenib)

Snippet

Sponsor: Abbott | Conditions: Hepatocellular Carcinoma Non-resectable, Hepatocellular Carcinoma Recurrent | Phase 3 | Status: TERMINATED